SUPPLEMENTAL MATERIAL
|
|
|
- Sherman Quinn
- 5 years ago
- Views:
Transcription
1 SUPPLEMENTAL MATERIAL
2 Table S1: Number and percentage of patients by age category Distribution of age Age<= (68%) 65<Age<=70 191(16%) 70<Age<= (10%) 75<Age<=80 60 (5%) Age>80 15 (1%)
3 Table S2 Baseline Characteristics by Age Baseline Age Quartiles Q1 Q2 Q3 (Age 54 (54<Age 60 (60<Age 67 Variable (n=330) (n=295) (n=279) Q4 (Age>67 (n=308) P-value for trend 1 Age (year) 50(47, 53) 57(56, 58) 64(62, 65) 72 (69, 75) Female 35 (11%) 26 (9%) 37 (13%) 50 (16%) White race 187 (57%) 189 (64%) 200 (72%) 251 (82%) <0.001 BMI (kg/m 2 ) 27 (24, 31) 27 (24, 30) 27 (24, 30) 26 (24, 29) Medical History: Diabetes 103 (31%) 121 (41%) 124 (44%) 130 (42%) Hypertension 178 (54%) 177 (60%) 159 (57%) 214 (70%) <0.001 PVD 36 (11%) 40 (14%) 42 (15%) 66 (21%) <0.001 Renal insufficiency 10 (3%) 16 (5%) 25 (9%) 43 (14%) <0.001 Stroke 23 (7%) 14 (5%) 21 (8%) 34 (11%) Atrial flutter/ fibrillation 19 (6%) 25 (9%) 42 (15%) 67 (22%) <0.001 Previous MI 250 (76%) 229 (78%) 208 (75%) 247 (80%) Hyperlipidemia 190 (58%) 174 (59%) 181 (65%) 185 (60%) Depression 24 (7%) 17 (6%) 15 (5%) 20 (7%) Current smoker 104 (32%) 64 (22%) 50 (18%) 34 (11%) <0.001 Previous PCI 45 (14%) 38 (13%) 38 (14%) 35 (11%) Previous CABG 8 (2%) 10 (3%) 11 (4%) 7 (2%) CCS angina class: No angina 106 (32%) 97 (33%) 91 (33%) 148 (48%) <0.001 I 42 (13%) 44 (15%) 52 (19%) 49 (16%) II 169 (51%) 141 (48%) 119 (43%) 96 (31%) <0.001 III 10 (3%) 12 (4%) 15 (5%) 11 (4%) IV 3 (1%) 1 (<1%) 2 (1%) 4 (1%) NYHA class: I 35 (11%) 50 (17%) 22 (8%) 32 (10%) II 185 (56%) 134 (45%) 157 (56%) 150 (49%) III 100 (30%) 106 (36%) 93 (33%) 113 (37%) IV 10 (3%) 5 (2%) 7 (3%) 13 (4%) Median systolic BP (mmhg) 120 (110, 130) 120 (110, 130) 120 (110, 130) 122 (110, 136) <0.001 Median heart rate (bpm) 76 (68, 84) 75 (68, 82) 74 (66, 82) 71 (63, 80) <0.001 Median 6 minute walk distance (meter) 352 (259, 434) 360 (273, 415) 340 (270, 400) 321 (250, 385) <0.001 Lab measures: Hemoglobin (g/dl) 14.3 (13.2, 13.9 (12.7, 13.7 (12.6, 13.6 (12.3, 15.4) 14.9) 14.8) 14.6) <0.001 Creatinine (mg/dl) 1.02 (0.90, 1.10 (0.97, 1.10 (0.94, 1.17 (1.00, 1.18) 1.23) 1.30) 1.40) <0.001 Sodium (meq/l) 139 (137, 140 (137, 142) 140 (138, 142) 140 (137, 0.086
4 142) 142) BUN (mg/dl) 22 (15, 37) 21 (16, 34) 21 (16, 36) 24 (18, 39) P-values for categorical variables are based on Cochran-Armitage Trend test. Spearman correlation test is performed to get the p-values for continuous variables and the continuous age variable.
5 Table S3 Baseline Left Ventricular Structure and Function and Coronary Anatomy by Age Variable Q1 (Age 54 (n=330) Baseline Age Quartiles Q2 (54<Age 60 (n=295) Q3 (60<Age 67 (n=279) Q4 (Age>67 (n=308) P-value for Trend 1 Structure and function: LVEF (%) 28 (22, 33) 28 (23, 35) 26 (21, 33) 28 (22, 34) ESVI 81 (62, 103) 81 (61, 98) 77 (60, 105) 77 (61, 98) EDVI 117 (92, 144) 113 (90, 139) 109 (87, 141) 108 (87, 135) E velocity (m/s) 0.70 (0.30, 0.90) 0.70 (0.50, 0.90) 0.70 (0.50, 0.90) 0.60 (0.50, 0.85) <0.001 A velocity (m/s) 0.60 (0.40, 0.80) 0.70 (0.50, 0.80) 0.73 (0.60, 0.90) 0.70 (0.60, 0.90) <0.001 E/A ratio 1.00 (0.75, 2.25) 1.00 (0.71, 1.78) 0.80 (0.63, 1.57) 0.75 (0.57, 1.33) <0.001 E/e ratio (septal) 14 (11, 20) 17 (12, 23) 15 (12, 24) 17 (11, 23) E/e ratio (lateral) 11 (8, 15) 12 (9, 16) 13 (9, 17) 12 (8, 17) Anterior akinesia or dyskinesia (%) 43 (30, 57) 43 (20, 50) 43 (29, 57) 40 (14, 57) MR severity: None or trace 123 (37%) 110 (37%) 106 (38%) 96 (31%) Mild 149 (45%) 130 (44%) 128 (46%) 147 (48%) Moderate 43 (13%) 47 (16%) 38 (14%) 53 (17%) Severe 14 (4%) 8 (3%) 7 (3%) 10 (3%) Coronary anatomy: No of vessels with stenosis 50% 1 46 (14%) 24 (8%) 24 (9%) 18 (6%) < (31%) 94 (32%) 87 (31%) 84 (27%) (56%) 177 (60%) 168 (60%) 205 (67%) Stenosis of proximal LAD 75% 242 (73%) 200 (68%) 185 (66%) 199 (65%) Duke CAD severity index 52 (39, 65) 65 (39, 77) 65 (39, 77) 65 (39, 77) P-values for categorical variables are based on Cochran-Armitage Trend test. Spearman correlation test is performed to get the p-values for continuous variables and the continuous age variable.
6 LVEF left ventricular ejection fraction, ESVI end systolic volume indexed, EDVI - end diastolic volume indexed, E - early diastolic filling velocity, A atrial contraction induced diastolic filling velocity wave, e - early diastolic myocardial velocity, MR mitral regurgitation, LAD left anterior descending, CAD coronary artery disease
7 Table S4 Procedural Details and Perioperative Complications by Age Variable Q1 (Age 54 (n=149) Baseline Age Quartiles Q2 (54<Age 60 (n=127) Q3 (60<Age 67 (n=131) Q4 (Age>67 (n=148) P-value for Trend 1 Number of conduits: 1 26 (17%) 10 (8%) 15 (12%) 18 (12%) (33%) 37 (29%) 42 (32%) 47 (32%) (40%) 60 (47%) 52 (40%) 64 (43%) (9%) 20 (16%) 22 (17%) 19 (13%) Number of arterial conduits: 0 11 (7%) 9 (7%) 12 (9%) 18 (12%) (83%) 104 (82%) 104 (79%) 115 (78%) (10%) 14 (11%) 15 (12%) 15 (10%) Number of distal anastomoses: 0 2 (1%) 2 (2%) 2 (2%) 1 (1%) (15%) 10 (8%) 14 (11%) 16 (11%) (28%) 27 (21%) 30 (23%) 30 (20%) (38%) 55 (43%) 50 (39%) 59 (40%) (15%) 23 (18%) 22 (17%) 31 (21%) (3%) 10 (8%) 12 (9%) 11 (7%) Off-pump bypass 40 (27%) 24 (19%) 25 (19%) 27 (18%) Total minutes on bypass 83 (63, 110) 92 (72, 125) 93 (66, 110) 89 (70, 126) Cross clamp time in minutes 50 (33, 67) 55 (41, 79) 54 (35, 72) 56 (39, 80) Intensive Care Unit length of stay in hours 52 (43, 87) 61 (42, 94) 49 (27, 97) 65 (40, 112) Perioperative complications Return to operating room 7 (5%) 9 (7%) 7 (5%) 12 (8%) Mediastinitis 3 (2%) 4 (3%) 2 (2%) 2 (1%) Other infection 9 (6%) 10 (8%) 8 (6%) 19 (13%) New onset Atrial Fibrillation 10 (7%) 20 (16%) 22 (17%) 38 (26%) <0.001 Worsening renal impairment 2 (1%) 4 (3%) 12 (9%) 16 (11%) <0.001 Intra-aortic balloon pump 25 (17%) 22 (17%) 24 (18%) 18 (12%) Inotropes for low cardiac output 45 (30%) 44 (35%) 56 (43%) 71 (48%) <0.001 Cardiac arrest requiring cardiopulmonary resuscitation 3 (2%) 3 (2%) 10 (8%) 7 (5%) Pulmonary edema requiring intubation 3 (2%) 3 (2%) 4 (3%) 4 (3%) Mortality within 30 days after CABG 3 (2%) 5 (4%) 10 (8%) 8 (5%) P-values for categorical variables are based on Cochran-Armitage Trend test. Spearman correlation test is performed to get the p-values for continuous variables and the continuous age variable.
8
9 Table S5: Medical therapy at randomization and at 10 years in each quartile of age by randomized therapy Q1 (Age 54 N(%) Q2 (54<Age 60 N(%) Q3 (60<Age 67 N(%) Q4 (Age>67 N(%) Overall MED CABG P Overall MED CABG P Overall MED CABG P Overall MED CABG P Betablocker Randomization 282 At 10 year 280 follow up (84) (84) (92) 112 (78) (92) (88) (79) 122 (84) 110 (80) (78) ACE inhibitor or ARB Randomization 288 At 10 year 269 follow up 149 (88) (84) 131 (92) 114 (86) (92) (75) (76) 153 (94) 107 (74) Statin Randomization 271 (82) At 10 year follow up 264 (86) 147 (86) (78) 129 (86) (82) (84) (81) 112 (84) (82) (78) (78) (82) 109 (75) 110 (80) 131 (80) Aspirin Randomization 273 At 10 year 272 follow up (88) (80) (86) (81) 116 (86) (81) 93 (76) (80) (72) (71) 124 (76) 106 (73) Warfarin Randomization 25 (8) At 10 year 39 follow up (13) 17 (10) 18 (11) 8 (5) 21 (14) (8) (17) 17 (11) 26 (18) 6 (4) 21 (16) (13) (18) 20 (15) 24 (19) 15 (10) 21 (17) (14) (26) 22 (15) 36 (26) 22 (13) 38 (26) Potassium sparing diuretic Randomization 161 (49) At 10 year follow up 173 (56) 84 (49) 86 (54) 77 (48) 87 (58) (46) (53) 70 (46) 75 (53) 67 (47) 72 (54) (49) (60) 67 (50) 80 (62) 69 (48) 70 (57) (40) (45) 55 (38) 59 (43) 67 (41) 68 (47)
10 Table S6: Cross overs from each treatment arm by quartile of age Randomized Treatment MED patients who crossed over to CABG CABG patients who crossed over to MED Q1 (Age 54 (n=330) 24/170 (14.1) 11/160 (6.9) Baseline Age Quartiles Q2 Q3 (54<Age 60 (60<Age 67 (n=295) (n=279) 13/152 (8.6) 16/135 (11.9) 16/143 (11.2) 13/144 (9.0) Q4 (Age>67 (n=308) 13/145 (9.0) 15/163 (9.2) Total (n=1212) 66/602 (11.0) P Value /610 (9.0) 0.62
11 Table S7: Hazard ratios and 95% confidence intervals for CABG plus optimal medical therapy versus optimal medical therapy alone by quartile of age Q2 Q1 (Age 54 (n=330) (54<Age 60 (n=295) Q3 (60<Age 67 (n=279) Q4 (Age>67 (n=308) All-cause death 0.66 (0.49, 0.89) 0.87 (0.64, 1.18) 1.00 (0.75, 1.33) 0.82 (0.63, 1.06) Cardiovascular death 0.61 (0.43, 0.85) 0.88 (0.63, 1.24) 1.02 (0.73, 1.44) 0.70 (0.50, 0.97) Death or cardiovascular hospitalization 0.55 (0.43, 0.71) 0.81 (0.62, 1.05) 0.85 (0.66, 1.09) 0.73 (0.57, 0.92)
12 Figure S1 Hazard ratio (solid line) and 95% confidence interval (grey area) for the effect of CABG vs medical therapy across the range of age- as treated analysis accounting for cross overs
ARIC HEART FAILURE HOSPITAL RECORD ABSTRACTION FORM. General Instructions: ID NUMBER: FORM NAME: H F A DATE: 10/13/2017 VERSION: CONTACT YEAR NUMBER:
ARIC HEART FAILURE HOSPITAL RECORD ABSTRACTION FORM General Instructions: The Heart Failure Hospital Record Abstraction Form is completed for all heart failure-eligible cohort hospitalizations. Refer to
Supplementary Online Content
Supplementary Online Content Inohara T, Manandhar P, Kosinski A, et al. Association of renin-angiotensin inhibitor treatment with mortality and heart failure readmission in patients with transcatheter
EACTS Adult Cardiac Database
EACTS Adult Cardiac Database Quality Improvement Programme List of changes to Version 2.0, 13 th Dec 2018, compared to version 1.0, 1 st May 2014. INTRODUCTORY NOTES This document s purpose is to list
This is the author s final accepted version.
Petrie, M. C. et al. (2016) Ten-year outcomes after coronary artery bypass grafting according to age in patients with heart failure and left ventricular systolic dysfunction: an analysis of the extended
ARIC HEART FAILURE HOSPITAL RECORD ABSTRACTION FORM
ARIC HEART FAILURE HOSPITAL RECORD ABSTRACTION FORM ID NUMBER: FORM NAME: H F A DATE: 10/01/2015 VERSION: D CONTACT YEAR NUMBER: FORM SEQUENCE NUMBER: General Instructions: The Heart Failure Hospital Record
Disclosure Information : No conflict of interest
Intravenous nicorandil improves symptoms and left ventricular diastolic function immediately in patients with acute heart failure : a randomized, controlled trial M. Shigekiyo, K. Harada, A. Okada, N.
DUKECATHR Dataset Dictionary
DUKECATHR Dataset Dictionary Version of DUKECATH dataset for educational use that has been modified to be unsuitable for clinical research or publication (Created Date and Time: 28OCT16 14:35) Table of
Randomized comparison of single versus double mammary coronary artery bypass grafting: 5 year outcomes of the Arterial Revascularization Trial
Randomized comparison of single versus double mammary coronary artery bypass grafting: 5 year outcomes of the Arterial Revascularization Trial Embargoed until 10:45 a.m. CT, Monday, Nov. 14, 2016 David
Quality Payment Program: Cardiology Specialty Measure Set
Quality Payment Program: Cardiology Specialty Set Title Number CMS Reporting Method(s) Heart Failure (HF): Angiotensin- Converting Enzyme (ACE) Inhibitor or Angiotensin Receptor Blocker (ARB) Therapy for
The Author(s) This article is published with open access by ASEAN Federation of Cardiology
DOI 10.7603/s40602-014-0011-3 ASEAN Heart Journal http://www.aseanheartjournal.org/ Vol. 22, no. 1, 60 65 (2014) ISSN: 2315-4551 Erratum Erratum to: Impact Of Sex On Clinical Characteristics And In-Hospital
Paris, August 28 th Gian Paolo Ussia on behalf of the CoreValve Italian Registry Investigators
Paris, August 28 th 2011 Is TAVI the definitive treatment in high risk patients? Impact Of Coronary Artery Disease In Elderly Patients Undergoing TAVI: Insight The Italian CoreValve Registry Gian Paolo
Supplementary Appendix
Supplementary Appendix This appendix has been provided by the authors to give readers additional information about their work. Supplement to: Solomon SD, Uno H, Lewis EF, et al. Erythropoietic response
APPENDIX F: CASE REPORT FORM
APPENDIX F: CASE REPORT FORM Instruction: Complete this form to notify all ACS admissions at your centre to National Cardiovascular Disease Registry. Where check boxes are provided, check ( ) one or more
Percutaneous coronary intervention of RIMA. The real challenge!
Percutaneous coronary intervention of RIMA The real challenge! Speaker's name: I do not have any potential conflict of interest Clinical Case 76-year old woman Previous History Actual Disease Diabetes
Quality Payment Program: Cardiology Specialty Measure Set
Measure Title * Reportable via PINNACLE α Reportable via Diabetes Collaborative CQMC v1.0 Measure High Priority Measure Cross Cutting Measure Heart Failure (HF): Angiotensin- Converting Enzyme (ACE) Inhibitor
Impact of Nicorandil on Renal Function in Patients With Acute Heart Failure and Pre-Existing Renal Dysfunction
Impact of Nicorandil on Renal Function in Patients With Acute Heart Failure and Pre-Existing Renal Dysfunction Masahito Shigekiyo, Kenji Harada, Ayumi Okada, Naho Terada, Hiroyoshi Yoshikawa, Akira Hirono,
Performance and Quality Measures 1. NQF Measure Number. Coronary Artery Disease Measure Set
Unless indicated, the PINNACLE Registry measures are endorsed by the American College of Cardiology Foundation and the American Heart Association and may be used for purposes of health care insurance payer
Evidence-Based Management of CAD: Last Decade Trials and Updated Guidelines
Evidence-Based Management of CAD: Last Decade Trials and Updated Guidelines Enrico Ferrari, MD Cardiac Surgery Unit Cardiocentro Ticino Foundation Lugano, Switzerland Conflict of Interests No conflict
Program Metrics. New Unique ID. Old Unique ID. Metric Set Metric Name Description. Old Metric Name
Program Metrics The list below includes the metrics that will be calculated by the PINNACLE Registry for the outpatient office setting. These include metrics for, Atrial Fibrillation, Hypertension and.
Safety of Single- Versus Multi-vessel Angioplasty for Patients with AMI and Multi-vessel CAD
Safety of Single- Versus Multi-vessel Angioplasty for Patients with AMI and Multi-vessel CAD Mun K. Hong, MD Associate Professor of Medicine Director, Cardiovascular Intervention and Research Weill Cornell
Alex versus Xience Registry Preliminary report
Interventional Cardiology Network Alex versus Xience Preliminary report Mariusz Gąsior 1,2, Marek Gierlotka 1, Lech Poloński 1,2 1 3rd Department of Cardiology, Medical University of Silesia Centre tor
The FORMA Early Feasibility Study: 30-Day Outcomes of Transcatheter Tricuspid Valve Therapy in Patients with Severe Secondary Tricuspid Regurgitation
The FORMA Early Feasibility Study: 30-Day Outcomes of Transcatheter Tricuspid Valve Therapy in Patients with Severe Secondary Tricuspid Regurgitation Susheel Kodali, MD Director, Structural Heart & Valve
Supplementary material
Supplementary material Comparison of propensity score methods and covariate adjustment a practical evaluation in four cardiovascular studies Table of Contents Supplementary tables Table S1: Results from
IN-HF on line: patient settings (Enrollement period= )
IN-HF on line: atient settings (Enrollement eriod= 1995-2018) N of centers (total) 187 N of centers (ts. AHF only) 13 N of centers (ts. CHF only) 71 N of centers (both ts. AHF and CHF) 103 N of atients
Revascularization for Patients with HFrEF: CABG and PCI and the Concept of Myocardial Viability
Revascularization for Patients with HFrEF: CABG and PCI and the Concept of Myocardial Viability 22nd Annual Heart Failure 2018: an Update on Therapy April 2018 Eric J. Velazquez, MD, FACP, FACC, FASE,
CHRONIC HEART FAILURE : WHAT ELSE COULD WE OFFER TO OUR PATIENTS? Cardiac Rehabilitation Society of Thailand
CHRONIC HEART FAILURE : WHAT ELSE COULD WE OFFER TO OUR PATIENTS? Cardiac Rehabilitation Society of Thailand ENHANCED EXTERNAL COUNTER PULSATION Piyanuj Ruckpanich, MD. Cardiac Rehabilitation Center Perfect
Emergency surgery in acute coronary syndrome
Emergency surgery in acute coronary syndrome Teerawoot Jantarawan Division of Cardiothoracic Surgery, Department of Surgery, Faculty of Medicine Siriraj Hospital, Mahidol University, Bangkok, Thailand
Rhythm Disorders 2017 TazKai LLC and NRSNG.com
Rhythm Disorders 1. Outline the conduction system of the heart. 2. What do the different portions of the EKG represent? 3. Define the following terms: a. Automaticity b. Conductivity c. Excitability d.
Form 136 WHI WOMEN S HEALTH INITIATIVE HEART FAILURE HOSPITAL RECORD ABSTRACTION FORM
Form 136 WHI WOMEN S HEALTH INITIATIVE HEART FAILURE HOSPITAL RECORD ABSTRACTION FORM FORM NAME: H T F DATE: 10/31/2012 VERSION: A MEMBER ID NUMBER: General Instructions: This form should be completed
Quality Measures MIPS CV Specific
Quality Measures MIPS CV Specific MEASURE NAME Atrial Fibrillation and Atrial Flutter: Chronic Anticoagulation Therapy CAHPS for MIPS Clinician/Group Survey Cardiac Rehabilitation Patient Referral from
HFpEF. April 26, 2018
HFpEF April 26, 2018 (J Am Coll Cardiol 2017;70:2476 86) HFpEF 50% or more (40-71%) of patients with CHF have preserved LV systolic function. HFpEF is an increasingly frequent hospital discharge. Outcomes
Hypothesis: When compared to conventional balloon angioplasty, cryoplasty post-dilation decreases the risk of SFA nses in-stent restenosis
Cryoplasty or Conventional Balloon Post-dilation of Nitinol Stents For Revascularization of Peripheral Arterial Segments Background: Diabetes mellitus is associated with increased risk of in-stent restenosis
Online Appendix (JACC )
Beta blockers in Heart Failure Collaborative Group Online Appendix (JACC013117-0413) Heart rate, heart rhythm and prognostic effect of beta-blockers in heart failure: individual-patient data meta-analysis
Surgery and device intervention for the elderly with heart failure: assessing the need. Devices and Technology for heart failure in 2011
Surgery and device intervention for the elderly with heart failure: assessing the need Devices and Technology for heart failure in 2011 Assessing cardiovascular function / prognosis (in the elderly): composite
New PINNACLE Measures The below measures for PINNACLE will be added as new measures to the outcomes reporting starting with Version 2.0.
New PINNACLE Measures The below measures for PINNACLE will be added as new measures to the outcomes reporting starting with Version 2.0. Measure Steward Measure Name Measure Description Rationale for Adding
Supplementary Material to Mayer et al. A comparative cohort study on personalised
Suppl. Table : Baseline characteristics of the patients. Characteristic Modified cohort Non-modified cohort P value (n=00) Age years 68. ±. 69.5 ±. 0. Female sex no. (%) 60 (0.0) 88 (.7) 0.0 Body Mass
Table 1 Baseline characteristics of 60 hemodialysis patients with atrial fibrillation and warfarin use
Table 1 Baseline characteristics of 60 hemodialysis patients with atrial fibrillation and warfarin use Baseline characteristics Users (n = 28) Non-users (n = 32) P value Age (years) 67.8 (9.4) 68.4 (8.5)
TSDA ACGME Milestones
TSDA ACGME Milestones Short MW and Edwards JA. Assessing resident milestones using a CASPE March 2012 Short MW and Edwards JA. Assessing resident milestones using a CASPE March 2012 Short
4. Which survey program does your facility use to get your program designated by the state?
STEMI SURVEY Please complete one survey for each TCD designation you have in your facility. There would be a maximum of three surveys completed if your facility was designated as a trauma, stroke and STEMI
Cardiovascular Health Practice Guideline Outpatient Management of Coronary Artery Disease 2003
Authorized By: Medical Management Guideline Committee Approval Date: 12/13/01 Revision Date: 12/11/03 Beta-Blockers Nitrates Calcium Channel Blockers MEDICATIONS Indicated in post-mi, unstable angina,
The MAIN-COMPARE Study
Long-Term Outcomes of Coronary Stent Implantation versus Bypass Surgery for the Treatment of Unprotected Left Main Coronary Artery Disease Revascularization for Unprotected Left MAIN Coronary Artery Stenosis:
ARIC. HEART FAILURE HOSPITAL RECORD ABSTRACTION FORM with SUPPLEMENTAL INFORMATION
ARIC HEART FAILURE HOSPITAL RECORD ABSTRACTION FORM with SUPPLEMENTAL INFORMATION ID NUMBER: FORM NAME: H F S DATE: 06/28/2012 VERSION: B Note: This form will only be done on a subset of participants.
Common Codes for ICD-10
Common Codes for ICD-10 Specialty: Cardiology *Always utilize more specific codes first. ABNORMALITIES OF HEART RHYTHM ICD-9-CM Codes: 427.81, 427.89, 785.0, 785.1, 785.3 R00.0 Tachycardia, unspecified
Heart Failure Clinician Guide JANUARY 2018
Kaiser Permanente National CLINICAL PRACTICE GUIDELINES Heart Failure Clinician Guide JANUARY 2018 Introduction This evidence-based guideline summary is based on the 2018 National Heart Failure Guideline.
Medical Management of Acute Heart Failure
Critical Care Medicine and Trauma Medical Management of Acute Heart Failure Mary O. Gray, MD, FAHA Associate Professor of Medicine University of California, San Francisco Staff Cardiologist and Training
Options for my no option Patients Treating Heart Conditions Via a Tiny Catheter
Options for my no option Patients Treating Heart Conditions Via a Tiny Catheter Nirat Beohar, MD Associate Professor of Medicine Director Cardiac Catheterization Laboratory, Medical Director Structural
Surgical Consensus Standards Endorsement Maintenance NQF-Endorsed Surgical Maintenance Standards (Phase I) Table of Contents
Table of Contents #0113: Participation in a Systematic Database for Cardiac Surgery... 2 #0114: Post-operative Renal Failure... 2 #0115: Surgical Re-exploration... 3 #0116: Anti-Platelet Medication at
CORONARY ARTERY BYPASS GRAFT (CABG) MEASURES GROUP OVERVIEW
CONARY ARTERY BYPASS GRAFT (CABG) MEASURES GROUP OVERVIEW 2015 PQRS OPTIONS F MEASURES GROUPS: 2015 PQRS MEASURES IN CONARY ARTERY BYPASS GRAFT (CABG) MEASURES GROUP: #43 Coronary Artery Bypass Graft (CABG):
Supplementary Table S1: Proportion of missing values presents in the original dataset
Supplementary Table S1: Proportion of missing values presents in the original dataset Variable Included (%) Missing (%) Age 89067 (100.0) 0 (0.0) Gender 89067 (100.0) 0 (0.0) Smoking status 80706 (90.6)
Title:Relation Between E/e' ratio and NT-proBNP Levels in Elderly Patients with Symptomatic Severe Aortic Stenosis
Author's response to reviews Title:Relation Between E/e' ratio and NT-proBNP Levels in Elderly Patients with Symptomatic Severe Aortic Stenosis Authors: Mihai Strachinaru (m.strachinaru@erasmusmc.nl) Bas
Congestive Heart Failure or Heart Failure
Congestive Heart Failure or Heart Failure Dr Hitesh Patel Ascot Cardiology Group Heart Failure Workshop April, 2014 Question One What is the difference between congestive heart failure and heart failure?
Measurement Name Beta-Blocker Therapy Prior Myocardial Infarction (MI)
Program Metrics The list below includes the metrics that will be calculated by the PINNACLE Registry for the outpatient office setting. These include metrics for Artery, Atrial Fibrillation, Hypertension
GALECTIN-3 PREDICTS LONG TERM CARDIOVASCULAR DEATH IN HIGH-RISK CORONARY ARTERY DISEASE PATIENTS
GALECTIN-3 PREDICTS LONG TERM CARDIOVASCULAR DEATH IN HIGH-RISK CORONARY ARTERY DISEASE PATIENTS Table of Contents List of authors pag 2 Supplemental figure I pag 3 Supplemental figure II pag 4 Supplemental
Treatment Of Preserved Cardiac Function Heart Failure with an Aldosterone antagonist (TOPCAT) AHA Nov 18, 2014 Update on Randomized Trials
Treatment Of Preserved Cardiac Function Heart Failure with an Aldosterone antagonist (TOPCAT) AHA Nov 18, 2014 Update on Randomized Trials Marc A. Pfeffer, MD, PhD; Brian Claggett, PhD; Susan F. Assmann,
Assessing Cardiac Risk in Noncardiac Surgery. Murali Sivarajan, M.D. Professor University of Washington Seattle, Washington
Assessing Cardiac Risk in Noncardiac Surgery Murali Sivarajan, M.D. Professor University of Washington Seattle, Washington Disclosure None. I have no conflicts of interest, financial or otherwise. CME
2016 Internal Medicine Preferred Specialty Measure Set
1 0059 Diabetes: Hemoglobin A1c (HbA1c) Poor Control (>9%): Percentage of patients 18-75 years of age with diabetes who had hemoglobin A1c > 9.0% during the measurement period 5 0081 Registry, EHR, 9 0105
8/28/2018. Pre-op Evaluation for non cardiac surgery. A quick review from 2007!! Disclosures. John Steuter, MD. None
Pre-op Evaluation for non cardiac surgery John Steuter, MD Disclosures None A quick review from 2007!! Fliesheret al, ACC/AHA 2007 Guidelines on Perioperative Cardiovascular Evaluation and are for Noncardiac
E/Ea is NOT an essential estimator of LV filling pressures
Euroecho Kopenhagen Echo in Resynchronization in 2010 E/Ea is NOT an essential estimator of LV filling pressures Wilfried Mullens, MD, PhD December 10, 2010 Ziekenhuis Oost Limburg Genk University Hasselt
Toledo Hospital Clinical Quality Indicators. Effective - Heart Attack
Effective - Heart Attack This page shows information on effective measures for patients who had heart attacks. "Effective care" means patients are given treatments that scientific evidence has shown leads
Heart Failure Clinician Guide JANUARY 2016
Kaiser Permanente National CLINICAL PRACTICE GUIDELINES Heart Failure Clinician Guide JANUARY 2016 Introduction This evidence-based guideline summary is based on the 2016 National Heart Failure Guideline.
Disclosures The PREVENT IV Trial was supported by Corgentech and Bristol-Myers Squibb
Saphenous Vein Grafts with Multiple Versus Single Distal Targets in Patients Undergoing Coronary Artery Bypass Surgery: One-Year Graft Failure and Five-Year Outcomes from the Project of Ex-vivo Vein Graft
Coronary artery disease (CAD) risk factors
Background Coronary artery disease (CAD) risk factors CAD Risk factors Hypertension Insulin resistance /diabetes Dyslipidemia Smoking /Obesity Male gender/ Old age Atherosclerosis Arterial stiffness precedes
Practice-Level Executive Summary Report
PINNACLE Registry Metrics 0003, Test Practice_NextGen [Rolling: 1st April 2015 to 31st March 2016 ] Generated on 5/11/2016 11:37:35 AM American College of Cardiology Foundation National Cardiovascular
Beta-blockers in Patients with Mid-range Left Ventricular Ejection Fraction after AMI Improved Clinical Outcomes
Beta-blockers in Patients with Mid-range Left Ventricular Ejection Fraction after AMI Improved Clinical Outcomes Seung-Jae Joo and other KAMIR-NIH investigators Department of Cardiology, Jeju National
Health Status after Transcatheter Mitral- Valve Repair in Patients with Heart Failure and Secondary Mitral Regurgitation: Results from the COAPT Trial
Health Status after Transcatheter Mitral- Valve Repair in Patients with Heart Failure and Secondary Mitral Regurgitation: Results from the COAPT Trial Suzanne V. Arnold, MD, MHA Saint Luke s Mid America
Primary and Secondary Prevention of Cardiovascular Disease. Frank J. Green, M.D., F.A.C.C. St. Vincent Medical Group
Primary and Secondary Prevention of Cardiovascular Disease Frank J. Green, M.D., F.A.C.C. St. Vincent Medical Group AHA Diet and Lifestyle Recommendations Balance calorie intake and physical activity to
Rationale for Prophylactic Support During Percutaneous Coronary Intervention
Rationale for Prophylactic Support During Percutaneous Coronary Intervention Navin K. Kapur, MD, FACC, FSCAI Assistant Director, Interventional Cardiology Director, Interventional Research Laboratories
STS CABG Composite Quality Rating. Participant STS Period Ending 12/31/2016
STS CABG Composite Quality Rating Quality Participant Score STS Mean Participant Distribution of Participant Scores Domain (98% CI) Participant Score Rating = STS Mean Jan 06 - Dec 06 Overall Jan 06 -
Can Angiographic Complete Revascularization Improve Outcomes for Patients with Decreased LV Function? NO!
Can Angiographic Complete Revascularization Improve Outcomes for Patients with Decreased LV Function? NO! Young-Hak Kim, MD, PhD Heart Institute, University of Ulsan College of Medicine Asan Medical Center,
Intraoperative application of Cytosorb in cardiac surgery
Intraoperative application of Cytosorb in cardiac surgery Dr. Carolyn Weber Heart Center of the University of Cologne Dept. of Cardiothoracic Surgery Cologne, Germany SIRS & Cardiopulmonary Bypass (CPB)
1 Week Followup - Intermacs
version date: 9/27/2017 1 Week Followup - Intermacs Followup Status (1 Week Followup (+/- 3 days)) Select one of the following Inpatient Outpatient Other Facility Unable to obtain follow-up information
Heart failure hospitalizations with preserved or reduced ejection fraction
Clinical profile and in-hospital outcomes in patients admitted for heart failure with preserved or reduced ejection fraction. EPI-CARDIO prospective registry Tajer, C; Mariani, J; de Abreu, M; Charask,
LEFT BUNDLE BRANCH BLOCK- BENIGN OR A HARBINGER OF HEART FAILURE? PROGNOSTIC INDICATOR?
LEFT BUNDLE BRANCH BLOCK- BENIGN OR A HARBINGER OF HEART FAILURE? PROGNOSTIC INDICATOR? Juan Cinca Department and Chair of Cardiology Hospital de la Santa Creu i Sant Pau Universitat Autònoma de Barcelona
Supplementary Online Content
Supplementary Online Content Inohara T, Xian Y, Liang L, et al. Association of intracerebral hemorrhage among patients taking non vitamin K antagonist vs vitamin K antagonist oral anticoagulants with in-hospital
Detailed Order Request Checklists for Cardiology
Next Generation Solutions Detailed Order Request Checklists for Cardiology 8600 West Bryn Mawr Avenue South Tower Suite 800 Chicago, IL 60631 www.aimspecialtyhealth.com Appropriate.Safe.Affordable 2018
Cardiogenic Shock. Carlos Cafri,, MD
Cardiogenic Shock Carlos Cafri,, MD SHOCK= Inadequate Tissue Mechanisms: Perfusion Inadequate oxygen delivery Release of inflammatory mediators Further microvascular changes, compromised blood flow and
Introducing the COAPT Trial
physician INFORMATION Eligible patients Symptomatic functional mitral regurgitation 3+ Not suitable candidates for open mitral valve surgery NYHA functional class II, III, or ambulatory IV Introducing
egfr > 50 (n = 13,916)
Saxagliptin and Cardiovascular Risk in Patients with Type 2 Diabetes Mellitus and Moderate or Severe Renal Impairment: Observations from the SAVOR-TIMI 53 Trial Supplementary Table 1. Characteristics according
HeFSSA Practitioners Program 2017 Theme The Patient Journey: Feel Good and Live Long. Case Study 2
HeFSSA Practitioners Program 2017 Theme The Patient Journey: Feel Good and Live Long Case Study 2 HEART FAILURE WITH MID-RANGE EJECTION FRACTION TREATMENT OPTIONS CLINICAL CASE MEDICAL HISTORY 59-year-old
Downloaded from:
Annemans, L; Danchin, N; Van de Werf, F; Pocock, S; Licour, M; Medina, J; Bueno, H (2016) Prehospital and in-hospital use of healthcare resources in patients surviving acute coronary syndromes: an analysis
Aortic Valve Practice Guidelines: What Has Changed and What You Need to Know
Aortic Valve Practice Guidelines: What Has Changed and What You Need to Know James F. Burke, MD Program Director Cardiovascular Disease Fellowship Lankenau Medical Center Disclosure Dr. Burke has no conflicts
Heart Failure. Cardiac Anatomy. Functions of the Heart. Cardiac Cycle/Hemodynamics. Determinants of Cardiac Output. Cardiac Output
Cardiac Anatomy Heart Failure Professor Qing ZHANG Department of Cardiology, West China Hospital www.blaufuss.org Cardiac Cycle/Hemodynamics Functions of the Heart Essential functions of the heart to cover
Revascularization after Drug-Eluting Stent Implantation or Coronary Artery Bypass Surgery for Multivessel Coronary Disease
Impact of Angiographic Complete Revascularization after Drug-Eluting Stent Implantation or Coronary Artery Bypass Surgery for Multivessel Coronary Disease Young-Hak Kim, Duk-Woo Park, Jong-Young Lee, Won-Jang
HFpEF, Mito or Realidad?
HFpEF, Mito or Realidad? Ileana L. Piña, MD, MPH Professor of Medicine and Epidemiology/Population Health Associate Chief for Academic Affairs -- Cardiology Montefiore-Einstein Medical Center Bronx, NY
Relationship between body mass index, coronary disease extension and clinical outcomes in patients with acute coronary syndrome
Relationship between body mass index, coronary disease extension and clinical outcomes in patients with acute coronary syndrome Helder Dores, Luís Bronze Carvalho, Ingrid Rosário, Sílvio Leal, Maria João
Diagnosis, treatment and outcome of acute heart failure in Africa Results of the THESUS-HF study
Diagnosis, treatment and outcome of acute heart failure in Africa Results of the THESUS-HF study A. Damasceno, A. Dzudie, A. Suliman, BA Abdou, C. Mondo, O. Ogah, M. Sani, DB. Weatherly, N. Schrueder,
1 Week Followup 5/27/2014. Nursing Home/Assisted Care Hospice Another hospital Rehabilitation Facility Unknown
1 Week Followup t Started Please answer all questions considering all time since the previous visit and current follow-up date. Print this Form Followup Status t Started Select one of the following Inpatient
Percutaneous Mechanical Circulatory Support Devices
Percutaneous Mechanical Circulatory Support Devices Daniel Vazquez RN, RCIS Miami Cardiac & Vascular Institute FINANCIAL DISCLOSURES none CASE STUDY CASE STUDY 52 year old gentlemen Complaining of dyspnea
Indications of Coronary Angiography Dr. Shaheer K. George, M.D Faculty of Medicine, Mansoura University 2014
Indications of Coronary Angiography Dr. Shaheer K. George, M.D Faculty of Medicine, Mansoura University 2014 Indications for cardiac catheterization Before a decision to perform an invasive procedure such
J. Schwitter, MD, FESC Section of Cardiology
J. Schwitter, MD, FESC Section of Cardiology CMR Center of the CHUV University Hospital Lausanne - CHUV Switzerland Centre de RM Cardiaque J. Schwitter, MD, FESC Section of Cardiology CMR Center of the
The Failing Heart in Primary Care
The Failing Heart in Primary Care Hamid Ikram How fares the Heart Failure Epidemic? 4357 patients, 57% women, mean age 74 years HFSA 2010 Practice Guideline (3.1) Heart Failure Prevention A careful and
Cardiac Cycle MCQ. Professor of Cardiovascular Physiology. Cairo University 2007
Cardiac Cycle MCQ Abdel Moniem Ibrahim Ahmed, MD Professor of Cardiovascular Physiology Cairo University 2007 1- Regarding the length of systole and diastole: a- At heart rate 75 b/min, the duration of
Antonio Colombo. Centro Cuore Columbus and S. Raffaele Scientific Institute, Milan, Italy. Miracor Symposium. Speaker: 15. Parigi: May 16-19, 2017
Parigi: May 16-19, 2017 Miracor Symposium Speaker: 15 Antonio Colombo Centro Cuore Columbus and S. Raffaele Scientific Institute, Milan, Italy Nothing to disclose PiCSO Impulse System Elective high risk
Diastology State of The Art Assessment
Diastology State of The Art Assessment Dr. Mohammad AlGhamdi Assistant professor, KSAU-HS Consultant Cardiologist King AbdulAziz Cardiac Center Ministry of National Guard Health Affairs Diagnostic Clinical
Welcome 17 Michigan TAVR Participating Hospitals!
Welcome 17 Michigan TAVR Participating Hospitals! 1 MICHIGAN TAVR BRIEF OVERVIEW HOW AND WHY PRE-TAVR IMAGING EVALUATION AND THE TVT Michael Grossman, MD Co-Director, BMC2 Coordinating Center Why Michigan
Chapter 4: Cardiovascular Disease in Patients With CKD
Chapter 4: Cardiovascular Disease in Patients With CKD Introduction Cardiovascular disease is an important comorbidity for patients with chronic kidney disease (CKD). CKD patients are at high-risk for
EACTS Adult Cardiac Database
EACTS Adult Cardiac Database Quality Improvement Programme Version 1.1, 15 May 2014 Contents 4 Patient demographics and other identifiers Patient identifier Race Age at operation Country code Gender Hospital
Objectives. Systolic Heart Failure: Definitions. Heart Failure: Historical Perspective 2/7/2009
Objectives Diastolic Heart Failure and Indications for Echocardiography in the Asian Population Damon M. Kwan, MD UCSF Asian Heart & Vascular Symposium 02.07.09 Define diastolic heart failure and differentiate
SONOGRAPHER & NURSE LED VALVE CLINICS
SONOGRAPHER & NURSE LED VALVE CLINICS Frequency of visits and alerts AORTIC STENOSIS V max > 4.0 m/s or EOA < 1.0 cm 2 V max 3.5 4.0 m/s + Ca+ V max 3.0 4.0 m/s or EOA 1.0-1.5 cm 2 V max 2.5 3.0 m/s every
Coronary Artery Disease: Revascularization (Teacher s Guide)
Stephanie Chan, M.D. Updated 3/15/13 2008-2013, SCVMC (40 minutes) I. Objectives Coronary Artery Disease: Revascularization (Teacher s Guide) To review the evidence on whether percutaneous coronary intervention